Canaccord reiterates Pharming stock rating on positive trial data

Canaccord reiterated a Buy and $38 price target on Pharming after Joenja showed a 26.4% mean reduction in spleen volume in a 13-patient Phase II study for genetically defined primary immunodeficiencies. The firm models roughly $1.0B in 2036 sales for genetically defined PIDs and $2.5B for CVID, though it assigns only a 50% probability of success for the broader indication. Offsetting the clinical progress, Q2 2026 revenue of $90.2M missed the $101.28M consensus as RUCONEST sales declined, prompting Oppenheimer to cut its target to $39 amid lowered guidance.

Analysis

PHAR’s valuation is increasingly a duration and execution question rather than a simple read-through from a small open-label dataset. The investable upside depends on whether broader PI3Kδ-linked disease can be segmented into reimbursable, genetically confirmed populations; a spleen-volume response alone will not establish that the addressable population supports the long-dated revenue assumptions embedded in bullish targets. The meaningful near-term issue is that legacy-product erosion can absorb incremental Joenja growth, leaving consensus vulnerable to further revenue-guide revisions before any expansion indication contributes commercially.

The October data presentation is a sentiment catalyst, but the key variables are durability, patient-level response consistency, steroid or immunoglobulin-use reduction, safety/discontinuations, and the relationship between genotype and response—not additional headline biomarker statistics. If the population is heavily enriched for APDS-like biology, investors should apply a substantial discount to extrapolations into heterogeneous CVID, where diagnostic definitions and payer requirements are likely to constrain uptake. A positive presentation may drive a days-to-weeks rerating in a thinly followed name, while a persuasive CVID dataset would matter more over the following 1-3 months.

Contrarian view: the apparent upside in published price targets may be less informative than the path to self-funded development. High gross margins do not prevent operating leverage from deteriorating if commercial investment rises faster than Joenja prescriptions while RUCONEST declines. The stock is likely under-owned enough that good data can create an outsized move, but that asymmetry is offset by binary evidence risk and a weak fundamental base-rate following a revenue miss.

Key Decisions for Investors

• Maintain PHAR as a catalyst watch, not a full-size core long, into the October 14-17 ESID presentation. Upgrade to a 50-75 bp tactical long only if disclosed durability and clinical-function endpoints support the imaging response; target a 15-25% event-driven rerating, with a 10-12% stop on safety, discontinuation, or heterogeneous-response evidence.
• Do not underwrite the broader-CVID revenue case before the expected Q4 2026 dataset. A long thesis should require management to quantify the genetically defined, payer-addressable population and provide a credible regulatory path; absent those items, treat any post-ESID spike as a liquidity opportunity rather than confirmation of terminal-value assumptions.
• For existing PHAR holders, reduce exposure if the next quarterly update shows Joenja growth failing to offset RUCONEST attrition or if full-year guidance is cut again. That would shift the debate from pipeline optionality to cash-burn and commercial-execution risk, likely compressing the multiple regardless of trial enthusiasm.
• Avoid using OPY or CF as hedges: neither has a direct economic linkage to PHAR’s clinical, reimbursement, or orphan-drug execution risks. If biotech beta hedging is needed, use a diversified biotech vehicle rather than forcing a single-name pair trade.